Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.59 |
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CREB1 | P16220 | 1/20 | 0.45 |
| ▸ | POLH | Q9Y253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119974 | 0.89 | ACE2 (0.60) | ADORA3PPARGABCB1MAPTACE2 | |
| SCHEMBL3811896 | 0.89 | ADORA3 (0.57) | ADORA3PPARGABCB1MAPTACE2 | |
| SCHEMBL13056300 | 0.88 | ADORA3 (0.62) | ADORA3PPARGABCB1MAPTACE2 | |
| SCHEMBL117535 | 0.88 | ADORA3 (0.69) | ADORA3PPARGABCB1MAPTACE2 | |
| SCHEMBL31031138 | 0.88 | ADORA3 (0.75) | ADORA3PPARGABCB1MAPTACE2 | |
| SCHEMBL174699 | 0.84 | ADORA3 (0.60) | ADORA3PPARGABCB1MAPTACE2 | |
| SCHEMBL176174 | 0.84 | ADORA3 (0.61) | ADORA3PPARGABCB1MAPTACE2 | |
| SCHEMBL176175 | 0.83 | ADORA3 (0.58) | ADORA3PPARGABCB1MAPTACE2 | |
| SCHEMBL12621081 | 0.82 | ABCB1 (0.62) | ADORA3PPARGABCB1MAPTABCG2 | |
| SCHEMBL1421560 | 0.82 | ACE2 (0.69) | ADORA3PPARGABCB1MAPTACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100297020-A1 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2010129138-A2 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297020-A1 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | PC, PCK1, PYGL | ADORA3 2000/4885PPARG 209/4885ABCB1 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.